Blinatumomab and Pembrolizumab.

about

Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.

P2860

Q38717851-97EC0542-F0F0-42E3-A1C0-D43DB4AEBC5A

P2860

Blinatumomab and Pembrolizumab.

Item

http://www.wikidata.org/entity/Q36110034

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Blinatumomab and Pembrolizumab.

@ast

Blinatumomab and Pembrolizumab.

@en

type

Item

label

Blinatumomab and Pembrolizumab.

@ast

Blinatumomab and Pembrolizumab.

@en

prefLabel

Blinatumomab and Pembrolizumab.

@ast

Blinatumomab and Pembrolizumab.

@en

P1476

Blinatumomab and Pembrolizumab.

@en

P2093

Dominic A Solimando

http://www.w3.org/2001/XMLSchema#string

Emily E Tabor

http://www.w3.org/2001/XMLSchema#string

J Aubrey Waddell

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

P304

269-273

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1310/HPJ5004-269

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26448656

http://www.w3.org/2001/XMLSchema#string

P932

4589878

http://www.w3.org/2001/XMLSchema#string

Blinatumomab and Pembrolizumab.

about

P2860

P2860

Blinatumomab and Pembrolizumab.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932